CN101126756A - 心脏肌钙蛋白作为晚期冠状动脉疾病及其并发症的指示物 - Google Patents
心脏肌钙蛋白作为晚期冠状动脉疾病及其并发症的指示物 Download PDFInfo
- Publication number
- CN101126756A CN101126756A CNA2007101421262A CN200710142126A CN101126756A CN 101126756 A CN101126756 A CN 101126756A CN A2007101421262 A CNA2007101421262 A CN A2007101421262A CN 200710142126 A CN200710142126 A CN 200710142126A CN 101126756 A CN101126756 A CN 101126756A
- Authority
- CN
- China
- Prior art keywords
- amount
- disease
- cardiac troponin
- natriuretic peptide
- troponin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000747 cardiac effect Effects 0.000 title claims abstract description 59
- 208000029078 coronary artery disease Diseases 0.000 title claims description 60
- 238000000034 method Methods 0.000 claims abstract description 67
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 230000000302 ischemic effect Effects 0.000 claims abstract description 17
- 108020001621 Natriuretic Peptide Proteins 0.000 claims description 60
- 102000004571 Natriuretic peptide Human genes 0.000 claims description 60
- 239000000692 natriuretic peptide Substances 0.000 claims description 60
- 102000004903 Troponin Human genes 0.000 claims description 59
- 108090001027 Troponin Proteins 0.000 claims description 59
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims description 17
- 230000001154 acute effect Effects 0.000 claims description 17
- 230000007211 cardiovascular event Effects 0.000 claims description 17
- 102000013394 Troponin I Human genes 0.000 claims description 12
- 108010065729 Troponin I Proteins 0.000 claims description 12
- 238000003745 diagnosis Methods 0.000 claims description 12
- 210000004351 coronary vessel Anatomy 0.000 claims description 9
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 2
- 206010027336 Menstruation delayed Diseases 0.000 claims 3
- 102400001263 NT-proBNP Human genes 0.000 claims 1
- 208000002193 Pain Diseases 0.000 abstract description 2
- 230000036407 pain Effects 0.000 abstract description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 66
- 239000003446 ligand Substances 0.000 description 43
- 102000004196 processed proteins & peptides Human genes 0.000 description 37
- 239000000523 sample Substances 0.000 description 33
- 208000010125 myocardial infarction Diseases 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 208000024891 symptom Diseases 0.000 description 21
- 238000003556 assay Methods 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 20
- 102000004987 Troponin T Human genes 0.000 description 19
- 108090001108 Troponin T Proteins 0.000 description 19
- 150000001413 amino acids Chemical group 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 206010019280 Heart failures Diseases 0.000 description 15
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 13
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 13
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 13
- 208000007814 Unstable Angina Diseases 0.000 description 12
- 230000001575 pathological effect Effects 0.000 description 12
- 208000000059 Dyspnea Diseases 0.000 description 10
- 206010013975 Dyspnoeas Diseases 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 230000037081 physical activity Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 8
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 8
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 208000019553 vascular disease Diseases 0.000 description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 7
- 101500026734 Homo sapiens NT-proBNP Proteins 0.000 description 7
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 7
- 230000002526 effect on cardiovascular system Effects 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 208000031225 myocardial ischemia Diseases 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 102100036836 Natriuretic peptides B Human genes 0.000 description 6
- 101710187802 Natriuretic peptides B Proteins 0.000 description 6
- 230000036755 cellular response Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 208000037923 polyvascular disease Diseases 0.000 description 6
- 208000013220 shortness of breath Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 5
- -1 NT-proANP Chemical compound 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 238000002586 coronary angiography Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010007558 Cardiac failure chronic Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 206010002388 Angina unstable Diseases 0.000 description 3
- 108091023037 Aptamer Proteins 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 208000037849 arterial hypertension Diseases 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004413 cardiac myocyte Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000004590 computer program Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000004217 heart function Effects 0.000 description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 238000004879 turbidimetry Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 238000003584 Ferrier rearrangement reaction Methods 0.000 description 2
- 101500026735 Homo sapiens Brain natriuretic peptide 32 Proteins 0.000 description 2
- 101710187800 Natriuretic peptides A Proteins 0.000 description 2
- 102100034296 Natriuretic peptides A Human genes 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007718 Stable Angina Diseases 0.000 description 2
- 206010071436 Systolic dysfunction Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- GMJHZZCVWDJKFB-UHFFFAOYSA-N 4-(4-aminophenyl)benzene-1,3-diamine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1N GMJHZZCVWDJKFB-UHFFFAOYSA-N 0.000 description 1
- HJCUTNIGJHJGCF-UHFFFAOYSA-N 9,10-dihydroacridine Chemical class C1=CC=C2CC3=CC=CC=C3NC2=C1 HJCUTNIGJHJGCF-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101800000267 CD40 ligand, soluble form Proteins 0.000 description 1
- 102400000432 CD40 ligand, soluble form Human genes 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108700020482 Maltose-Binding protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 238000012092 latex agglutination test Methods 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 208000019267 mild heart failure Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000019266 moderate heart failure Diseases 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000002182 neurohumoral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000018655 severe necrosis Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06119017.9 | 2006-08-16 | ||
| EP06119017A EP1890153A1 (en) | 2006-08-16 | 2006-08-16 | Cardiac troponin as an indicator of advanced coronary artery disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101126756A true CN101126756A (zh) | 2008-02-20 |
Family
ID=36968707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101421262A Pending CN101126756A (zh) | 2006-08-16 | 2007-08-16 | 心脏肌钙蛋白作为晚期冠状动脉疾病及其并发症的指示物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7927812B2 (enExample) |
| EP (1) | EP1890153A1 (enExample) |
| JP (1) | JP4823170B2 (enExample) |
| CN (1) | CN101126756A (enExample) |
| CA (1) | CA2597585A1 (enExample) |
| ES (1) | ES2390359T3 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725633A (zh) * | 2009-12-03 | 2012-10-10 | 雅培制药有限公司 | 用于诊断心肌细胞损害的测定 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1925943A1 (en) | 2006-11-21 | 2008-05-28 | F. Hoffman-la Roche AG | Means and methods for optimization of diagnostic and therapeutic approaches in chronic artery disease based on the detection of Troponin T and NT-proBNP. |
| EP2089719A2 (en) * | 2006-11-21 | 2009-08-19 | Roche Diagnostics GmbH | Means and methods for optimization of diagnostic and therapeutic approaches in chronic artery disease based on troponin t and nt-probnp |
| JP5419968B2 (ja) * | 2008-05-21 | 2014-02-19 | エフ．ホフマン−ラ ロシュ アーゲー | 心臓治療を必要とする個体におけるｌ−ｆａｂｐ、ナトリウム利尿ペプチド及び心筋トロポニン |
| WO2009144229A1 (en) * | 2008-05-27 | 2009-12-03 | F. Hoffmann-La Roche Ag | Method for risk reduction in glycemic control |
| JP2011523072A (ja) * | 2008-06-13 | 2011-08-04 | エフ．ホフマン−ラ ロシュ アーゲー | １型糖尿病を有する患者の合併症の評価 |
| WO2009150249A1 (en) * | 2008-06-13 | 2009-12-17 | Roche Diagnostics Gmbh | Nt-probnp as prognostic indicator for the development of end stage renal disease in diabetes mellitus |
| JP2012502290A (ja) * | 2008-09-11 | 2012-01-26 | エフ．ホフマン−ラ ロシュ アーゲー | メタボリックシンドロームを有する患者におけるナトリウム利尿ペプチドおよびアディポネクチン |
| WO2010042126A1 (en) * | 2008-10-11 | 2010-04-15 | Nanosphere, Inc. | Methods and assays to assess cardiac risk and ischemia |
| AU2010259022B2 (en) | 2009-06-08 | 2016-05-12 | Singulex, Inc. | Highly sensitive biomarker panels |
| KR20120101064A (ko) * | 2009-11-13 | 2012-09-12 | 비쥐 메디신, 인코포레이티드 | 심근 경색의 위험 인자 및 예측 |
| EP2609427B1 (en) * | 2010-08-26 | 2015-01-21 | Roche Diagnostics GmbH | Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure |
| EP2638400A4 (en) * | 2010-11-12 | 2014-05-07 | Univ Johns Hopkins | ALBUMIN-RELATED PROTEIN / PEPTIDE COMPLEX AS BIOMARKER FOR DISEASE |
| CN102816764A (zh) * | 2011-06-07 | 2012-12-12 | 浦项工科大学校产学协力团 | 特异性结合于人心肌肌钙蛋白ⅰ的dna适体 |
| WO2014066419A2 (en) * | 2012-10-22 | 2014-05-01 | Stealth Peptides International, Inc. | Methods for reducing risks associated with heart failure and factors associated therewith |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| US6520971B1 (en) | 2000-11-27 | 2003-02-18 | Scimed Life Systems, Inc. | Full thickness resection device control handle |
| US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| ATE439588T1 (de) | 2001-05-04 | 2009-08-15 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
| US6461828B1 (en) * | 2001-09-04 | 2002-10-08 | Syn X Pharma | Conjunctive analysis of biological marker expression for diagnosing organ failure |
| MXPA03004105A (es) * | 2002-05-14 | 2004-10-15 | Hoffmann La Roche | Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores. |
| US7074194B2 (en) * | 2003-05-19 | 2006-07-11 | Ischemia Technologies, Inc. | Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin |
| DE10351238A1 (de) * | 2003-11-03 | 2005-06-02 | Roche Diagnostics Gmbh | Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern |
-
2006
- 2006-08-16 EP EP06119017A patent/EP1890153A1/en not_active Withdrawn
-
2007
- 2007-08-10 ES ES07114174T patent/ES2390359T3/es active Active
- 2007-08-13 US US11/837,714 patent/US7927812B2/en active Active
- 2007-08-15 JP JP2007211829A patent/JP4823170B2/ja active Active
- 2007-08-15 CA CA002597585A patent/CA2597585A1/en not_active Abandoned
- 2007-08-16 CN CNA2007101421262A patent/CN101126756A/zh active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102725633A (zh) * | 2009-12-03 | 2012-10-10 | 雅培制药有限公司 | 用于诊断心肌细胞损害的测定 |
| CN102725633B (zh) * | 2009-12-03 | 2016-02-03 | 雅培制药有限公司 | 用于诊断心肌细胞损害的测定 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1890153A1 (en) | 2008-02-20 |
| ES2390359T3 (es) | 2012-11-12 |
| US7927812B2 (en) | 2011-04-19 |
| JP2008046129A (ja) | 2008-02-28 |
| CA2597585A1 (en) | 2008-02-16 |
| JP4823170B2 (ja) | 2011-11-24 |
| US20080081344A1 (en) | 2008-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4823170B2 (ja) | 進行型冠動脈疾患およびその合併症のインジケーターとしての心筋トロポニン | |
| JP4731525B2 (ja) | 心因性と肺因性の急性呼吸窮迫を鑑別する手段と方法 | |
| JP4944185B2 (ja) | 症状のある患者における急性および慢性の心筋壊死の区別のための手段と方法 | |
| JP5015318B2 (ja) | Ｇｄｆ−１５及びナトリウム利尿ペプチドを用いた、心房細動を有する患者の心不全を評価するための手段及び方法 | |
| US8497095B2 (en) | Biochemical markers for acute pulmonary embolism | |
| JP5719379B2 (ja) | 心臓手術患者における腎不全を予測するためのｇｄｆ−１５ | |
| JP5198565B2 (ja) | 心疾患に関連する又は関連しないｇｄｆ−１５の上昇の区別のための手段及び方法 | |
| JP2011501113A (ja) | 急性冠症候群を有する患者での既存の心筋機能不全の評価のためのナトリウム利尿ペプチド／トロポニン比 | |
| JP2020034564A (ja) | 心不全リスクの予測改善のためのバイオマーカー | |
| EP1890154B1 (en) | Cardiac troponin as an indicator of advanced coronary artery disease | |
| JP2011509403A (ja) | Ｇｄｆ−１５に基づいて救急室を受診する患者のリスクを評価するための手段及び方法 | |
| JP2013527453A (ja) | 急性炎症における生存および回復を推定するためのｇｄｆ−１５に基づく手段および方法 | |
| JP5306218B2 (ja) | トロポニンＴおよびＮＴ−ｐｒｏＢＮＰの検出に基づく慢性動脈疾患での診断および治療的アプローチの最適化のための手段および方法 | |
| JP2010537212A (ja) | 息切れの原因の鑑別におけるサーファクタントプロテインｂ及びｄ | |
| JP4664939B2 (ja) | 息切れの心臓原因および肺原因を鑑別するための手段および方法 | |
| EP1925943A1 (en) | Means and methods for optimization of diagnostic and therapeutic approaches in chronic artery disease based on the detection of Troponin T and NT-proBNP. | |
| US7977105B2 (en) | Myoglobin as early predictor of myocardial infarction | |
| JP2010528306A (ja) | 心筋梗塞の早期予測因子としてのｈ−ｆａｂｐ | |
| JP2011523072A (ja) | １型糖尿病を有する患者の合併症の評価 | |
| US20110081671A1 (en) | Vascular markers in the remodeling of cardiac injury | |
| HK1117909A (en) | Cardiac troponin as an indicator of advanced coronary artery disease and its complications | |
| HK1118334A (en) | Means and methods for the differentiation of cardiac and pulmonary causes of acute shortness of breath |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1117909 Country of ref document: HK |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20080220 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1117909 Country of ref document: HK |